基线皮肤细胞因子RNA原位杂交谱与湿疹性皮炎患者度普利尤单抗应答相关
回顾性分析61例接受度普利尤单抗治疗的湿疹性皮炎患者活检标本,用RNA原位杂交检测2型(IL4、IL13)、1型(IFN-γ)和3型(IL17A、IL17F、IL22)炎症标志物。完全应答16例、部分应答37例、无应答8例。IL13表达增高与最佳应答相关,无应答者IL13较低而1型和3型细胞因子相对较高。局限性为回顾性方法和无应答组样本量小。
要点
- IL13表达增高与度普利尤单抗最佳应答相关。
- 无应答者IL13表达较低,1型和3型细胞因子相对较高。
- 某些组织学特征倾向于与度普利尤单抗应答改善相关。
核心结论
- 细胞因子RNA原位杂交可能有助于湿疹性疾病的治疗选择。
- 炎症性皮肤病的个体化治疗选择可能成为可能。
研究设计与样本
- 回顾性分析61例接受度普利尤单抗治疗的湿疹性皮炎患者的活检标本,其中90.2%符合Hanifin-Rajka特应性皮炎标准。
- 采用RNA原位杂交检测2型(IL4、IL13)、1型(干扰素γ)和3型(IL17A、IL17F、IL22)炎症标志物,并评估组织学特征。
- 比较完全应答者(n=16)、部分应答者(n=37)和无应答者(n=8)之间的模式。
主要发现
- IL13表达增高与度普利尤单抗最佳应答相关。
- 无应答者倾向于表达较少的IL13和相对较高水平的1型和3型细胞因子。
- 某些组织学特征倾向于与度普利尤单抗应答改善相关。
局限性
- 回顾性方法。
- 无应答组样本量小。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Dupilumab has revolutionized the treatment of atopic dermatitis. However, not all patients respond optimally, and this may relate to underlying molecular heterogeneity. Nevertheless, clinically useful and accessible methods to assess such heterogeneity have not been developed. OBJECTIVE: We assessed whether cytokine staining and/or histologic features correlate with clinical response to dupilumab in patients with eczematous dermatitis. METHODS: We retrospectively analyzed biopsies from 61 patients with eczematous dermatitis treated with dupilumab (90.2% met Hanifin-Rajka criteria for atopic dermatitis). RNA in situ hybridization was used to measure markers of type 2 (interleukin [IL]4, IL13), type 1 (interferon gamma) and type 3 (IL17A, IL17F, IL22) inflammation. Histologic features were also assessed. Patterns were compared among complete (n = 16), partial (n = 37), and nonresponders (n = 8) to dupilumab. RESULTS: We found that increased IL13 expression was associated with optimal response to dupilumab. In contrast, nonresponders tended to express less IL13 and relatively greater levels of type 1 and 3 cytokines. In addition, certain histologic features tended to correlate with improved response to dupilumab. LIMITATIONS: Retrospective approach and small size of the nonresponder group. CONCLUSION: Cytokine RNA in situ hybridization may aid in treatment selection for eczematous disorders. Moreover, personalization of treatment selection for inflammatory skin diseases may be possible.
引用
- Singh K, Valido K, Swallow M, et al. Baseline skin cytokine profiles determined by RNA in situ hybridization correlate with response to dupilumab in patients with eczematous dermatitis. J Am Acad Dermatol. 2023. PMID: 36780951. doi:10.1016/j.jaad.2022.12.052
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。